Catherine W. Parham, M.D., is chief medical officer and executive vice president of medical and clinical affairs at Sirtex. As the company’s principal medical expert, she develops the strategic vision for our clinical trial portfolio.
Before joining Sirtex in 2022, Dr. Parham served as vice president and head of global medical affairs for Astellas Gene Therapies. Prior to that, she was vice president, global program lead, R&D, of Takeda Pharmaceutical’s Plasma-Derived Therapies business unit, and held leadership positions at Shire, Pfizer, GE Healthcare, Johnson & Johnson, and Millennium Pharmaceuticals. Additionally, Dr. Parham has served as an instructor of anesthesia and critical care at both Harvard Medical School/Beth Israel Deaconess Medical Center and Boston University School of Medicine.
Dr. Parham earned her bachelor’s degrees in engineering and literature from Massachusetts Institute of Technology. She holds a Doctor of Medicine degree from Boston University School of Medicine and an MBA from Northeastern University in Boston. She completed postgraduate medical training in surgery and adult and pediatric cardiovascular anesthesia at Harvard-affiliated Beth Israel Deaconess and Tufts-New England Medical Center, respectively.